Daily Supplementation of D-ribose Shows No Therapeutic Benefits in the MHC-I Transgenic Mouse Model of Inflammatory Myositis
Open Access
- 13 June 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e65970
Abstract
Current treatments for idiopathic inflammatory myopathies (collectively called myositis) focus on the suppression of an autoimmune inflammatory response within the skeletal muscle. However, it has been observed that there is a poor correlation between the successful suppression of muscle inflammation and an improvement in muscle function. Some evidence in the literature suggests that metabolic abnormalities in the skeletal muscle underlie the weakness that continues despite successful immunosuppression. We have previously shown that decreased expression of a purine nucleotide cycle enzyme, adenosine monophosphate deaminase (AMPD1), leads to muscle weakness in a mouse model of myositis and may provide a mechanistic basis for muscle weakness. One of the downstream metabolites of this pathway, D-ribose, has been reported to alleviate symptoms of myalgia in patients with a congenital loss of AMPD1. Therefore, we hypothesized that supplementing exogenous D-ribose would improve muscle function in the mouse model of myositis. We treated normal and myositis mice with daily doses of D-ribose (4 mg/kg) over a 6-week time period and assessed its effects using a battery of behavioral, functional, histological and molecular measures. Treatment with D-ribose was found to have no statistically significant effects on body weight, grip strength, open field behavioral activity, maximal and specific forces of EDL, soleus muscles, or histological features. Histological and gene expression analysis indicated that muscle tissues remained inflamed despite treatment. Gene expression analysis also suggested that low levels of the ribokinase enzyme in the skeletal muscle might prevent skeletal muscle tissue from effectively utilizing D-ribose. Treatment with daily oral doses of D-ribose showed no significant effect on either disease progression or muscle function in the mouse model of myositis.Keywords
This publication has 25 references indexed in Scilit:
- The role of TRAIL in mediating autophagy in myositis skeletal muscle: A potential nonimmune mechanism of muscle damageArthritis & Rheumatism, 2011
- Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammationArthritis Research & Therapy, 2010
- Upregulation of MHC class I in transgenic mice results in reduced force‐generating capacity in slow‐twitch muscleMuscle & Nerve, 2009
- Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunctionArthritis & Rheumatism, 2005
- Effects of Oral Ribose on Muscle Metabolism during Bicycle Ergometer in AMPD-Deficient PatientsAnnals of Nutrition and Metabolism, 1991
- Metabolism of D-ribose administered continuously to healthy persons and to patients with myoadenylate deaminase deficiencyJournal of Molecular Medicine, 1989
- Myoadenylate deaminase deficiency: Successful symptomatic therapy by high dose oral administration of riboseJournal of Molecular Medicine, 1986
- Myoadenylate deaminase deficiency: Inherited and acquired formsBiochemical Medicine, 1985
- Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle.Journal of Clinical Investigation, 1984
- FAILURE OF D-RIBOSE IN MYOADENYLATE DEAMINASE DEFICIENCYThe Lancet, 1983